NeuropathologyNEUROBISITENCT02767583
Assessment of the Prevalence of Small Fiber Peripheral Neuropathy Among Non-diabetic Obese Patients
A study testing Exams in people with Neuropathology, run by Fondation Hôpital Saint-Joseph at 1 site in France.
Trial summary
Background / rational: Obesity is associated with significant comorbidities including type 2 diabetes (insulin resistance), heart disease, stroke, hypertension, sleep apnea syndrome, dyslipidemia, cancer, hepatobiliary diseases, orthopedic complications and psychosocial impact 1 . Read more about this study
- Who is it for?
- Ages 18 to 60 years
- Conditions the study is for
- Neuropathology
- What is being tested?
- Exams
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 16 participants
- Where
- 1 siteFrance
- Study dates
- 2 Mar 2015to 30 Jun 2017
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- morbidly obese patients:
- BMI 35-55 kg / m²
- Male or female
- Age> 18 and <60 years
- Consultant for the first time at the Centre of obesity of Paris Saint Joseph Hospital Group.
Who cannot join
- Diabetes known treaty
- Co-morbidity related to obesity: heart disease, respiratory failure
- Other causes of peripheral neuropathy:
- Alcohol Poisoning
- Renal failure (clearance ≤ 60 mL / min)
- Infection HIV, hepatitis B, C
Show all 14Show fewer
- Deficiencies vitamins B1, B6, B12, folate
- Treatment with vitamin B6
- thyroid disease antecedent
- Previous history of autoimmune disease
- Previous history of cancer
- Previous history of neurotoxic treatment (chemotherapy, etc. see list provided in annex)
- ICU hospitalization antecedent> 48 hours.
- known history of peripheral neuropathy.
Trial locations and contacts
1 site in 1 country.
France1 site
Groupe Hopitalier Paris Saint Joseph Service de neurologie
Paris, Île-de-France Region, 75014
About this study
Background / rational:
Obesity is associated with significant comorbidities including type 2 diabetes (insulin resistance), heart disease, stroke, hypertension, sleep apnea syndrome, dyslipidemia, cancer, hepatobiliary diseases, orthopedic complications and psychosocial impact 1 .
Read more
Peripheral neuropathy is a known complication in the type I and II diabetes and glucose intolerance and metabolic syndrome in 2. Outside of diabetes (type I and II) that are associated with cardiovascular risk high vascular, presence of metabolic syndrome constitutes in itself a well demonstrated vascular risk factor. Its definition requires the presence of three elements from the following 5: abdominal obesity (high waist circumference), high blood pressure, high fasting blood sugar, high triglycerides and / low HDL-cholesterol 3.
This peripheral neuropathy predominantly affects sensory fibers of small poorly myelinated diameter (Aδ fibers and C) and autonomous sensory fibers and is called small fiber neuropathy 4. The cardinal sign of NAION is the presence of neuropathic pain but abnormalities in physical examination are often absent and conventional electromyography is faulted to make the diagnosis. These small fibers are also constituent of the autonomic nervous system and causes damage autonomic dysfunction that can manifest the cardiovascular system (hypotension, cardiac conduction disorders), digestive, sweat, sphincter. neuropathy of the diagnosis of small fibers is suggested clinically by the presence of neuropathic pain often contrasting with a normal clinical examination. The confirmation is based on electrophysiology with various techniques and quantification of intra-epidermal nerve fibers.
Main objective / secondary:
Primary objective :
To determine the prevalence of a small fiber peripheral neuropathy in nondiabetic obese patients, by measuring skin conductance ion Chlorine (Sudoscan®) evaluating small fibers C autonomic
Secondary objectives:
- Evaluation of the prevalence of occurrence of peripheral neuropathy by Sudoscan® during follow-up after treatment of obese patients with bariatric surgery (months) M1, 3, 6, 9, 12.
- Correlation of results obtained Sudoscan® quantitative sensory testing (QST) Thermotest® evaluating small sensory fibers Aδ, among non-operated non-diabetic obese patients and in the postoperative follow-up (months) M1, 3, 6, 9, 12.
- Characterization of electromyographic parameters (motor and sensory conduction) in patients with a skin conductance measured by lowered Sudoscan® and / or a threshold of sensitivity to pain increased Thermotest®.
- Correlation between the presence of a small fiber neuropathy in non-diabetic obese subjects with clinical and biological parameters collected.
Methodology Design: prospective, single-center Study duration: 24 months (estimate: 3-5 patients included / week of 15 patients collected in central obesity / week) including 12 months of inclusion.
Number of topics to include: 100 over a period of one year to adjust to the rhythm of the inclusions.
As mentioned, patients will be a measure of impedance of the skin to products chlorine ions by the sweat glands via the Sudoscan®, marketed and used among diabetic patients or not for the detection of violations neuropathic (cf. references and CE certificate attached to the dossier).
The Thermotest® is also marketed and used in diabetic and non-diabetic patients (see references and CE certificate attached to the dossier).
Our center has gained experience of these techniques for the detection of peripheral neuropathy in several patient populations (diabetes and cancer in particular); manipulators (doctors and technicians) are trained in these techniques.
Read the detailed description
Main objective / secondary:
Primary objective :
To determine the prevalence of a small fiber peripheral neuropathy in nondiabetic obese patients, by measuring skin conductance ion Chlorine (Sudoscan®) evaluating small fibers C autonomic
Secondary objectives:
- Evaluation of the prevalence of occurrence of peripheral neuropathy by Sudoscan® during follow-up after treatment of obese patients with bariatric surgery (months) M1, 3, 6, 9, 12.
- Correlation of results obtained Sudoscan® quantitative sensory testing (QST) Thermotest® evaluating small sensory fibers Aδ, among non-operated non-diabetic obese patients and in the postoperative follow-up (months) M1, 3, 6, 9, 12.
- Characterization of electromyographic parameters (motor and sensory conduction) in patients with a skin conductance measured by lowered Sudoscan® and / or a threshold of sensitivity to pain increased Thermotest®.
- Correlation between the presence of a small fiber neuropathy in non-diabetic obese subjects with clinical and biological parameters collected.
Inclusion / non-inclusion:
Inclusion criteria:
morbidly obese patients:
- BMI 35-55 kg / m²,
- Male or female,
- Age> 18 and <60 years,
- Consultant for the first time at the Centre of obesity of Paris Saint Joseph Hospital Group.
Exclusion criteria:
- Diabetes known treaty
- Co-morbidity related to obesity: heart disease, respiratory failure
- Other causes of peripheral neuropathy:
- Alcohol Poisoning
- Renal failure (clearance ≤ 60 mL / min)
- Infection HIV, hepatitis B, C
- Deficiencies vitamins B1, B6, B12, folate
- Treatment with vitamin B6
- thyroid disease antecedent
- Previous history of autoimmune disease
- Previous history of cancer
- Previous history of neurotoxic treatment (chemotherapy, etc. see list provided in annex)
- ICU hospitalization antecedent> 48 hours.
- known history of peripheral neuropathy.
Development of the study:
If patients the eligibility criteria, it will be proposed at the first consultation in central obesity, participate in a clinical study to assess the prevalence of subclinical damage peripheral nerves by simple and painless rapid measurement of skin conductance on the palm of the feet with the Sudoscan® device during the consultation and a Thermotest®, as well as monitoring during the various follow-up consultation after any bariatric surgery or not. This monitoring will be done by the same neurophysiological tests.
- During the preoperative assessment that will be conducted in the planned hospital in Diabetology Service, written information will be given to patient and no objection will be drawn, then the following tests will be done:
- The measurement of skin conductance by Sudoscan® and the extent of the painful sensitivity to temperature Thermotest® will be made for all patients included in the study.
- If the records Sudoscan® skin conductance less than 60μS, we propose a Electroneuromyography the patient as usual on GHPSJ.
- Measurement of weight, height, waist circumference and hip circumference patient
- The DN4 scale and Uens clinical neuropathy score.
- A measurement of blood pressure will be
- A biological sample will be taken on an empty stomach.
- For patients with plantar skin conductance will be lowered <60μSiemens and / or whose pain threshold will warm significantly elevated (Thermotest®), if necessary electromyogram will be realized in the second time (appointment given to the output consultation with the endocrinologist.
- During the postoperative follow-up usually expected for this type of surgery, 1, 3, 6, 9 and 12 months will be made the same clinical examinations than those made during the preoperative assessment and the type of surgery performed. Laboratory tests will be carried out in the usual care for surgical patients.
Methodology Design: prospective, single-center Study duration: 24 months (estimate: 3-5 patients included / week of 15 patients collected in central obesity / week) including 12 months of inclusion.
Number of topics to include: 100 over a period of one year to adjust to the rhythm of the inclusions.
As mentioned, patients will be a measure of impedance of the skin to products chlorine ions by the sweat glands via the Sudoscan®, marketed and used among diabetic patients or not for the detection of violations neuropathic (cf. references and CE certificate attached to the dossier).
The Thermotest® is also marketed and used in diabetic and non-diabetic patients (see references and CE certificate attached to the dossier).
Our center has gained experience of these techniques for the detection of peripheral neuropathy in several patient populations (diabetes and cancer in particular); manipulators (doctors and technicians) are trained in these techniques.
Data collection for each patient:
- Clinical data:
- Age
- Gender
- BMI
- Size
- Weight
- Waist
- Hips
- Report on waist hips
- Blood pressure: systolic, diastolic, mean
- Score Questionnaire DN4 (presence or absence of neuropathic pain)
- Score Uens
- electrophysiological data
- skin conductance (μSiemens) measured by the Sudoscan®
- Plants Average feet (right, left)
- Thermotest®: average score of sensitivity threshold to pain in plantar warm level (average of the soles of both feet).
- Electromyography:
- Sensitive Conduction:
- sural nerve left and right (lateral malleolus collection, antidromic calf stimulation), radial nerve left and right (wrist collection, antidromic stimulation forearm)
- Amplitude (mV)
- VCS (sensory conduction velocity m / s)
- Motor Conduction:
- Sciatic nerve popliteal internal right and left (short collection flexor hallucis longus, ankle stimulation)
- distal motor latency (ms)
- amplitude of CMAP (mV)
- Latency wave F shortest (ms).
- tibial nerve left and right anterior (short collection extensor hallucis longus, ankle stimulation under neck of the fibula, above-neck of the fibula)
- distal motor latency (ms)
- Amplitude of PGAM 3 to stimulation points (mV)
- PNT leg and neck of the fibula (m / s).
- Latency wave F shortest (ms).
- EMG needle:
- Muscles studied: tibialis anterior right, wide left inner, right brachioradialis.
- Rest Activities: yes / no
- Activation Pattern:
- normal Interferential
- Intermediate with poor temporal summation
- Poor with temporal summation
- Single with temporal summation
- Biological data:
- Fasting glucose
- HbA1c
- Triglycerides
- Total cholesterol
- HDL cholesterol
- LDL Cholesterol
- uricaemia
- SGOT, SGPT, gammaGT
- urea, creatinine
- creatinine clearance
- Microalbuminuria on sample
- serum folate,
- vitamins D, B1 and B12,
- calcemia
- albumin
- NFS, CRP
- Electrophoresis + plasma protein immunofixation.
Data processing :
For each subject will be awarded an identifier (original name and surname - year of birth) and the data will be entered on a computer file which will be sent to the statistician in charge of analyzing the GHPSJ site. There will be no exchange of personal data.
Statistical analysis :
The patient will be considered to have a small fiber neuropathy, symptomatic or not, when the skin conductance of chloride ions will be below the threshold for 60μSiemens soles. The prevalence shall be calculated from that definition.
Stratified by age will be made during the statistical analysis.
A test will be performed to analyze the statistical relationship between:
Skin conductance AND
- BMI,
- size,
- Girth
- Waist circumference ratio / hip circumference
- Sex,
- DN4 score,
- The score Uens,
- The biological parameters studied: fasting blood glucose, HbA1c, total cholesterol, HDL cholesterol, triglycerides, CRP, serum uric acid.
- Threshold of pain sensitivity warm on the feet by Thermotest.
- Type of surgery for surgical patients.
Ethics / Regulatory:
The patient will be informed orally of the objective of the study, a leaflet it will also be provided (attached); its information and not be drawn opposition in his file.
All tests are part of the normal patient care. The ethics of the CPP Ile de France approved this study on march 15th 2015. The manager research center will be the hospital group Paris Saint-Joseph (GHPSJ).
partnerships
Impeto the company, the manufacturer will provide Sudoscan® (loan agreement) the machine for the duration of the study.
GHPSJ ensure the neurologist time, diabetologist, biologist and ARC necessary and will provide the Thermotest® machine for the duration of the study.
Conflicts of interest :
No conflict of interest.
- Conditions
- Neuropathology
- Being tested
- Exams
- Keywords
- Neuropathology
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ExamsDevice
Patients the eligibility criteria will be proposed at the first consultation in central obesity, participate in a clinical study to assess the prevalence of subclinical damage peripheral nerves by simple and painless rapid measurement of skin conductance on the palm of the feet with the Sudoscan® device during the consultation and a Thermotest®, as well as monitoring during the various follow-up consultation after any bariatric surgery or not. This monitoring will be done by the same neurophysiological tests.
| Study group | Role | What they receive |
|---|---|---|
| Non diabetic obese | Experimental | Non diabetic obese with BMI 35-55 kg / m2 consulting for the first time at the Centre of obesity of Paris Saint Joseph Hospital Group will got a themotest and Sudoscan exams de determine their neuropathology. Receives: Device: Exams |
What is being measured
The primary outcome is the main question the study is designed to answer.
Assessment of Chlorine ion production change
Patients will be a measure of impedance of the skin to products chlorine ions by the sweat glands via the Sudoscan® Device, marketed and used among diabetic patients or not for the detection of violations neuropathic (cf. references and CE certificate attached to the dossier)
Measured: at inclusion then 1 month, 3 months, 6months and 12 months after surgery
Assessment of Temperature changing sensitivity
Patients will be measured their sensitivity to temperature changing using the Thermotest Device
Measured: At inclusion then 1 month, 3 months, 6months and 12 months after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 May 2016 (estimated)
- Study start2 Mar 2015
- Primary completion30 Jun 2017
- Study completion30 Jun 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (8)Papers the sponsor has linked to this study.
- Other trials for NeuropathologyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Screening
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 16 participants (actual)
Sponsor and investigators
- Lead sponsor
- Fondation Hôpital Saint-Joseph
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Mathieu ZUBER, MD, Principal investigator, Groupe Hospitalier Paris Saint-Joseph (FRANCE)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02767583
- Sponsor's protocol ID
- Neuropathies and obesity
- Acronym
- NEUROBISITE
- Status last verified
- Mar 2018
- First submitted
- 4 May 2016
- Last updated
- 14 Mar 2018
- Results posted
- No
- Data monitoring committee
- No
Publications
Smith AG, Lessard M, Reyna S, Doudova M, Singleton JR. The diagnostic utility of Sudoscan for distal symmetric peripheral neuropathy. J Diabetes Complications. 2014 Jul-Aug;28(4):511-6. doi: 10.1016/j.jdiacomp.2014.02.013. Epub 2014 Mar 6.
PubMed 24661818Kopelman PG. Obesity as a medical problem. Nature. 2000 Apr 6;404(6778):635-43. doi: 10.1038/35007508.
PubMed 10766250Herman RM, Brower JB, Stoddard DG, Casano AR, Targovnik JH, Herman JH, Tearse P. Prevalence of somatic small fiber neuropathy in obesity. Int J Obes (Lond). 2007 Feb;31(2):226-35. doi: 10.1038/sj.ijo.0803418. Epub 2006 Jun 13.
PubMed 16770330Philippi N, Vinzio S, Collongues N, Vix M, Boehm N, Tranchant C, Echaniz-Laguna A. [Peripheral neuropathies after bariatric surgery]. Rev Neurol (Paris). 2011 Aug-Sep;167(8-9):607-14. doi: 10.1016/j.neurol.2011.01.011. Epub 2011 Apr 22. French.
PubMed 21514611Thaisetthawatkul P, Collazo-Clavell ML, Sarr MG, Norell JE, Dyck PJ. A controlled study of peripheral neuropathy after bariatric surgery. Neurology. 2004 Oct 26;63(8):1462-70. doi: 10.1212/01.wnl.0000142038.43946.06.
PubMed 15505166Sumner CJ, Sheth S, Griffin JW, Cornblath DR, Polydefkis M. The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology. 2003 Jan 14;60(1):108-11. doi: 10.1212/wnl.60.1.108.
PubMed 12525727Devigili G, Tugnoli V, Penza P, Camozzi F, Lombardi R, Melli G, Broglio L, Granieri E, Lauria G. The diagnostic criteria for small fibre neuropathy: from symptoms to neuropathology. Brain. 2008 Jul;131(Pt 7):1912-25. doi: 10.1093/brain/awn093. Epub 2008 Jun 4.
PubMed 18524793Casellini CM, Parson HK, Richardson MS, Nevoret ML, Vinik AI. Sudoscan, a noninvasive tool for detecting diabetic small fiber neuropathy and autonomic dysfunction. Diabetes Technol Ther. 2013 Nov;15(11):948-53. doi: 10.1089/dia.2013.0129. Epub 2013 Jul 27.
PubMed 23889506
Study at a glance
From the registry record, last updated by the sponsor on 14 Mar 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Assessment of the Prevalence of Small Fiber Peripheral Neuropathy Among Non-diabetic Obese Patients
- ClinicalTrials.gov ID
- NCT02767583
- Acronym / sponsor ID
- NEUROBISITE / Neuropathies and obesity
- Conditions
- Neuropathology
- Keywords
- Neuropathology
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 16 participants (actual)
- Lead sponsor
- Fondation Hôpital Saint-JosephUniversity, hospital or other
- Study start
- 2 Mar 2015 (actual)
- Primary completion
- 30 Jun 2017 (actual)
- Study completion
- 30 Jun 2017 (actual)
- First posted
- 10 May 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background / rational:
Obesity is associated with significant comorbidities including type 2 diabetes (insulin resistance), heart disease, stroke, hypertension, sleep apnea syndrome, dyslipidemia, cancer, hepatobiliary diseases, orthopedic complications and psychosocial impact 1 .
Peripheral neuropathy is a known complication in the type I and II diabetes and glucose intolerance and metabolic syndrome in 2. Outside of diabetes (type I and II) that are associated with cardiovascular risk high vascular, presence of metabolic syndrome constitutes in itself a well demonstrated vascular risk factor. Its definition requires the presence of three elements from the following 5: abdominal obesity (high waist circumference), high blood pressure, high fasting blood sugar, high triglycerides and / low HDL-cholesterol 3.
This peripheral neuropathy predominantly affects sensory fibers of small poorly myelinated diameter (Aδ fibers and C) and autonomous sensory fibers and is called small fiber neuropathy 4. The cardinal sign of NAION is the presence of neuropathic pain but abnormalities in physical examination are often absent and conventional electromyography is faulted to make the diagnosis. These small fibers are also constituent of the autonomic nervous system and causes damage autonomic dysfunction that can manifest the cardiovascular system (hypotension, cardiac conduction disorders), digestive, sweat, sphincter. neuropathy of the diagnosis of small fibers is suggested clinically by the presence of neuropathic pain often contrasting with a normal clinical examination. The confirmation is based on electrophysiology with various techniques and quantification of intra-epidermal nerve fibers.
Main objective / secondary:
Primary objective :
To determine the prevalence of a small fiber peripheral neuropathy in nondiabetic obese patients, by measuring skin conductance ion Chlorine (Sudoscan®) evaluating small fibers C autonomic
Secondary objectives:
- Evaluation of the prevalence of occurrence of peripheral neuropathy by Sudoscan® during follow-up after treatment of obese patients with bariatric surgery (months) M1, 3, 6, 9, 12.
- Correlation of results obtained Sudoscan® quantitative sensory testing (QST) Thermotest® evaluating small sensory fibers Aδ, among non-operated non-diabetic obese patients and in the postoperative follow-up (months) M1, 3, 6, 9, 12.
- Characterization of electromyographic parameters (motor and sensory conduction) in patients with a skin conductance measured by lowered Sudoscan® and / or a threshold of sensitivity to pain increased Thermotest®.
- Correlation between the presence of a small fiber neuropathy in non-diabetic obese subjects with clinical and biological parameters collected.
Methodology Design: prospective, single-center Study duration: 24 months (estimate: 3-5 patients included / week of 15 patients collected in central obesity / week) including 12 months of inclusion.
Number of topics to include: 100 over a period of one year to adjust to the rhythm of the inclusions.
As mentioned, patients will be a measure of impedance of the skin to products chlorine ions by the sweat glands via the Sudoscan®, marketed and used among diabetic patients or not for the detection of violations neuropathic (cf. references and CE certificate attached to the dossier).
The Thermotest® is also marketed and used in diabetic and non-diabetic patients (see references and CE certificate attached to the dossier).
Our center has gained experience of these techniques for the detection of peripheral neuropathy in several patient populations (diabetes and cancer in particular); manipulators (doctors and technicians) are trained in these techniques.
Detailed description
Main objective / secondary:
Primary objective :
To determine the prevalence of a small fiber peripheral neuropathy in nondiabetic obese patients, by measuring skin conductance ion Chlorine (Sudoscan®) evaluating small fibers C autonomic
Secondary objectives:
- Evaluation of the prevalence of occurrence of peripheral neuropathy by Sudoscan® during follow-up after treatment of obese patients with bariatric surgery (months) M1, 3, 6, 9, 12.
- Correlation of results obtained Sudoscan® quantitative sensory testing (QST) Thermotest® evaluating small sensory fibers Aδ, among non-operated non-diabetic obese patients and in the postoperative follow-up (months) M1, 3, 6, 9, 12.
- Characterization of electromyographic parameters (motor and sensory conduction) in patients with a skin conductance measured by lowered Sudoscan® and / or a threshold of sensitivity to pain increased Thermotest®.
- Correlation between the presence of a small fiber neuropathy in non-diabetic obese subjects with clinical and biological parameters collected.
Inclusion / non-inclusion:
Inclusion criteria:
morbidly obese patients:
- BMI 35-55 kg / m²,
- Male or female,
- Age> 18 and <60 years,
- Consultant for the first time at the Centre of obesity of Paris Saint Joseph Hospital Group.
Exclusion criteria:
- Diabetes known treaty
- Co-morbidity related to obesity: heart disease, respiratory failure
- Other causes of peripheral neuropathy:
- Alcohol Poisoning
- Renal failure (clearance ≤ 60 mL / min)
- Infection HIV, hepatitis B, C
- Deficiencies vitamins B1, B6, B12, folate
- Treatment with vitamin B6
- thyroid disease antecedent
- Previous history of autoimmune disease
- Previous history of cancer
- Previous history of neurotoxic treatment (chemotherapy, etc. see list provided in annex)
- ICU hospitalization antecedent> 48 hours.
- known history of peripheral neuropathy.
Development of the study:
If patients the eligibility criteria, it will be proposed at the first consultation in central obesity, participate in a clinical study to assess the prevalence of subclinical damage peripheral nerves by simple and painless rapid measurement of skin conductance on the palm of the feet with the Sudoscan® device during the consultation and a Thermotest®, as well as monitoring during the various follow-up consultation after any bariatric surgery or not. This monitoring will be done by the same neurophysiological tests.
- During the preoperative assessment that will be conducted in the planned hospital in Diabetology Service, written information will be given to patient and no objection will be drawn, then the following tests will be done:
- The measurement of skin conductance by Sudoscan® and the extent of the painful sensitivity to temperature Thermotest® will be made for all patients included in the study.
- If the records Sudoscan® skin conductance less than 60μS, we propose a Electroneuromyography the patient as usual on GHPSJ.
- Measurement of weight, height, waist circumference and hip circumference patient
- The DN4 scale and Uens clinical neuropathy score.
- A measurement of blood pressure will be
- A biological sample will be taken on an empty stomach.
- For patients with plantar skin conductance will be lowered <60μSiemens and / or whose pain threshold will warm significantly elevated (Thermotest®), if necessary electromyogram will be realized in the second time (appointment given to the output consultation with the endocrinologist.
- During the postoperative follow-up usually expected for this type of surgery, 1, 3, 6, 9 and 12 months will be made the same clinical examinations than those made during the preoperative assessment and the type of surgery performed. Laboratory tests will be carried out in the usual care for surgical patients.
Methodology Design: prospective, single-center Study duration: 24 months (estimate: 3-5 patients included / week of 15 patients collected in central obesity / week) including 12 months of inclusion.
Number of topics to include: 100 over a period of one year to adjust to the rhythm of the inclusions.
As mentioned, patients will be a measure of impedance of the skin to products chlorine ions by the sweat glands via the Sudoscan®, marketed and used among diabetic patients or not for the detection of violations neuropathic (cf. references and CE certificate attached to the dossier).
The Thermotest® is also marketed and used in diabetic and non-diabetic patients (see references and CE certificate attached to the dossier).
Our center has gained experience of these techniques for the detection of peripheral neuropathy in several patient populations (diabetes and cancer in particular); manipulators (doctors and technicians) are trained in these techniques.
Data collection for each patient:
- Clinical data:
- Age
- Gender
- BMI
- Size
- Weight
- Waist
- Hips
- Report on waist hips
- Blood pressure: systolic, diastolic, mean
- Score Questionnaire DN4 (presence or absence of neuropathic pain)
- Score Uens
- electrophysiological data
- skin conductance (μSiemens) measured by the Sudoscan®
- Plants Average feet (right, left)
- Thermotest®: average score of sensitivity threshold to pain in plantar warm level (average of the soles of both feet).
- Electromyography:
- Sensitive Conduction:
- sural nerve left and right (lateral malleolus collection, antidromic calf stimulation), radial nerve left and right (wrist collection, antidromic stimulation forearm)
- Amplitude (mV)
- VCS (sensory conduction velocity m / s)
- Motor Conduction:
- Sciatic nerve popliteal internal right and left (short collection flexor hallucis longus, ankle stimulation)
- distal motor latency (ms)
- amplitude of CMAP (mV)
- Latency wave F shortest (ms).
- tibial nerve left and right anterior (short collection extensor hallucis longus, ankle stimulation under neck of the fibula, above-neck of the fibula)
- distal motor latency (ms)
- Amplitude of PGAM 3 to stimulation points (mV)
- PNT leg and neck of the fibula (m / s).
- Latency wave F shortest (ms).
- EMG needle:
- Muscles studied: tibialis anterior right, wide left inner, right brachioradialis.
- Rest Activities: yes / no
- Activation Pattern:
- normal Interferential
- Intermediate with poor temporal summation
- Poor with temporal summation
- Single with temporal summation
- Biological data:
- Fasting glucose
- HbA1c
- Triglycerides
- Total cholesterol
- HDL cholesterol
- LDL Cholesterol
- uricaemia
- SGOT, SGPT, gammaGT
- urea, creatinine
- creatinine clearance
- Microalbuminuria on sample
- serum folate,
- vitamins D, B1 and B12,
- calcemia
- albumin
- NFS, CRP
- Electrophoresis + plasma protein immunofixation.
Data processing :
For each subject will be awarded an identifier (original name and surname - year of birth) and the data will be entered on a computer file which will be sent to the statistician in charge of analyzing the GHPSJ site. There will be no exchange of personal data.
Statistical analysis :
The patient will be considered to have a small fiber neuropathy, symptomatic or not, when the skin conductance of chloride ions will be below the threshold for 60μSiemens soles. The prevalence shall be calculated from that definition.
Stratified by age will be made during the statistical analysis.
A test will be performed to analyze the statistical relationship between:
Skin conductance AND
- BMI,
- size,
- Girth
- Waist circumference ratio / hip circumference
- Sex,
- DN4 score,
- The score Uens,
- The biological parameters studied: fasting blood glucose, HbA1c, total cholesterol, HDL cholesterol, triglycerides, CRP, serum uric acid.
- Threshold of pain sensitivity warm on the feet by Thermotest.
- Type of surgery for surgical patients.
Ethics / Regulatory:
The patient will be informed orally of the objective of the study, a leaflet it will also be provided (attached); its information and not be drawn opposition in his file.
All tests are part of the normal patient care. The ethics of the CPP Ile de France approved this study on march 15th 2015. The manager research center will be the hospital group Paris Saint-Joseph (GHPSJ).
partnerships
Impeto the company, the manufacturer will provide Sudoscan® (loan agreement) the machine for the duration of the study.
GHPSJ ensure the neurologist time, diabetologist, biologist and ARC necessary and will provide the Thermotest® machine for the duration of the study.
Conflicts of interest :
No conflict of interest.
Study design
- Primary purpose
- Screening
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Non diabetic obese | Experimental | Device: ExamsNon diabetic obese with BMI 35-55 kg / m2 consulting for the first time at the Centre of obesity of Paris Saint Joseph Hospital Group will got a themotest and Sudoscan exams de determine their neuropathology. |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- morbidly obese patients:
- BMI 35-55 kg / m²
- Male or female
- Age> 18 and <60 years
- Consultant for the first time at the Centre of obesity of Paris Saint Joseph Hospital Group.
Key exclusion criteria (14 listed)
- Diabetes known treaty
- Co-morbidity related to obesity: heart disease, respiratory failure
- Other causes of peripheral neuropathy:
- Alcohol Poisoning
- Renal failure (clearance ≤ 60 mL / min)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ExamsPatients the eligibility criteria will be proposed at the first consultation in central obesity, participate in a clinical study to assess the prevalence of subclinical damage peripheral nerves by simple and painless rapid measurement of skin conductance on the palm of the feet with the Sudoscan® device during the consultation and a Thermotest®, as well as monitoring during the various follow-up consultation after any bariatric surgery or not. This monitoring will be done by the same neurophysiological tests. | Device | Non diabetic obese |
Primary outcome
Assessment of Chlorine ion production change
Time frame: at inclusion then 1 month, 3 months, 6months and 12 months after surgery
Patients will be a measure of impedance of the skin to products chlorine ions by the sweat glands via the Sudoscan® Device, marketed and used among diabetic patients or not for the detection of violations neuropathic (cf. references and CE certificate attached to the dossier)
Assessment of Temperature changing sensitivity
Time frame: At inclusion then 1 month, 3 months, 6months and 12 months after surgery
Patients will be measured their sensitivity to temperature changing using the Thermotest Device
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Mar 2018.
- Background: PubMed 24661818Smith AG, Lessard M, Reyna S, Doudova M, Singleton JR. The diagnostic utility of Sudoscan for distal symmetric peripheral neuropathy. J Diabetes Complications. 2014 Jul-Aug;28(4):511-6. doi: 10.1016/j.jdiacomp.2014.02.013. Epub 2014 Mar 6.
- Results publication: PubMed 10766250Kopelman PG. Obesity as a medical problem. Nature. 2000 Apr 6;404(6778):635-43. doi: 10.1038/35007508.
- Results publication: PubMed 16770330Herman RM, Brower JB, Stoddard DG, Casano AR, Targovnik JH, Herman JH, Tearse P. Prevalence of somatic small fiber neuropathy in obesity. Int J Obes (Lond). 2007 Feb;31(2):226-35. doi: 10.1038/sj.ijo.0803418. Epub 2006 Jun 13.
- Results publication: PubMed 21514611Philippi N, Vinzio S, Collongues N, Vix M, Boehm N, Tranchant C, Echaniz-Laguna A. [Peripheral neuropathies after bariatric surgery]. Rev Neurol (Paris). 2011 Aug-Sep;167(8-9):607-14. doi: 10.1016/j.neurol.2011.01.011. Epub 2011 Apr 22. French.
- Results publication: PubMed 15505166Thaisetthawatkul P, Collazo-Clavell ML, Sarr MG, Norell JE, Dyck PJ. A controlled study of peripheral neuropathy after bariatric surgery. Neurology. 2004 Oct 26;63(8):1462-70. doi: 10.1212/01.wnl.0000142038.43946.06.
- Results publication: PubMed 12525727Sumner CJ, Sheth S, Griffin JW, Cornblath DR, Polydefkis M. The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology. 2003 Jan 14;60(1):108-11. doi: 10.1212/wnl.60.1.108.
- Results publication: PubMed 18524793Devigili G, Tugnoli V, Penza P, Camozzi F, Lombardi R, Melli G, Broglio L, Granieri E, Lauria G. The diagnostic criteria for small fibre neuropathy: from symptoms to neuropathology. Brain. 2008 Jul;131(Pt 7):1912-25. doi: 10.1093/brain/awn093. Epub 2008 Jun 4.
- Results publication: PubMed 23889506Casellini CM, Parson HK, Richardson MS, Nevoret ML, Vinik AI. Sudoscan, a noninvasive tool for detecting diabetic small fiber neuropathy and autonomic dysfunction. Diabetes Technol Ther. 2013 Nov;15(11):948-53. doi: 10.1089/dia.2013.0129. Epub 2013 Jul 27.
Related trials for Neuropathology
RecruitingPhase 1/2
Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma
Glioblastoma Multiforme
RecruitingObservational study
Early Detection of Selected Neuropathologies in Motor Vehicle Drivers
Multiple Sclerosis, Parkinson Disease
RecruitingObservational study
Cognitive Functioning in Adults With Somatic Diseases and General Population From a Biopsychosocial Perspective
Aphasia, Development, Human
Recruiting
Exploratory Study of Cerebral Perfusion and Metabolic Alterations and Neurocognitive Disorders in Patients With Unruptured Arteriovenous Malformations Before and After Surgical Treatment
Unruptured Brain Arteriovenous Malformation
RecruitingPhase 1
TREAD: Time Restricted Eating Intervention for Alzheimer's Disease
Mild Cognitive Impairment, Alzheimer Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mathieu ZUBER, MD principal investigator
Groupe Hospitalier Paris Saint-Joseph (FRANCE)
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Exams in people with Neuropathology, run by Fondation Hôpital Saint-Joseph at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Mar 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Assessment of Chlorine ion production change (time frame: at inclusion then 1 month, 3 months, 6months and 12 months after surgery). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02767583, which also lists 8 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Mar 2018.